Biosimilars And The Need For Real-World Evidence
This article was originally published in SRA
Executive Summary
The success of biosimilars will depend on a range of factors, including local policies on interchangeability, harmonization of naming conventions, reimbursement decisions, and physician adoption. Real-world evidence will help to support data generated by clinical trials and fill the evidence gap for doctors, patients and payers, say Jaclyn Bosco and Nancy Dreyer.